Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

Background: In progressive multiple sclerosis (MS), glial activation is thought to be a relevant mechanism of disability progression. Therefore, in vivo assessment of the glial cell activity is, in the emerging treatment era of primary progressive MS (PPMS), more important than ever. Objectives: To...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelhak, Ahmed, Hottenrott, Tilman, Morenas-Rodríguez, Estrella, Suárez-Calvet, Marc, Zettl, Uwe K., Haass, Christian, Meuth, Sven G., Rauer, Sebastian, Otto, Markus, Tumani, Hayrettin, Huss, André
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443875/
https://www.ncbi.nlm.nih.gov/pubmed/30972011
http://dx.doi.org/10.3389/fneur.2019.00280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443875/
https://www.ncbi.nlm.nih.gov/pubmed/30972011
http://dx.doi.org/10.3389/fneur.2019.00280

Ejemplares similares